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 37 
Abstract 38 
Purpose: Circulating tumor cells (CTCs) have clinical relevance, but their study has 39 
been limited by their low frequency. Experimental Design: We evaluated liquid 40 
biopsies by apheresis to increase CTC yield from patients suffering from metastatic 41 
prostate cancer, allow precise gene copy number calls, and study disease 42 
heterogeneity. Results: Apheresis was well-tolerated and allowed the separation of 43 
large numbers of CTCs; the average CTC yield from 7.5mls of peripheral blood was 44 
167 CTCs, whereas the average CTC yield per apheresis (mean volume: 59.5mls) was 45 
12546 CTCs. Purified single CTCs could be isolated from apheresis product by FACS 46 
sorting; copy number aberration (CNA) profiles of 185 single CTCs from 14 patients 47 
revealed the genomic landscape of lethal prostate cancer and identified complex intra-48 
patient, inter-cell, genomic heterogeneity missed on bulk biopsy analyses. 49 
Conclusions: Apheresis facilitated the capture of large numbers of CTCs non-50 
invasively with minimal morbidity and allowed the deconvolution of intra-patient 51 
heterogeneity and clonal evolution.  52 
  53 
Research. 
on April 24, 2019. © 2018 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on August 9, 2018; DOI: 10.1158/1078-0432.CCR-18-0862 
3 
Statement of Significance:  54 
Apheresis is well-tolerated and is a non-invasive alternative to tumor tissue biopsies, 55 
substantially increasing circulating tumor cell yields and allowing the study of tumor 56 
evolution and intra-patient heterogeneity during treatment. Serial, repeated, apheresis 57 
can interrogate disease evolution, drive key therapeutic decisions and transform 58 
prostate cancer drug development.  59 
 60 
  61 
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Introduction: 62 
Prostate cancer (PC) remains a major cause of male cancer-related deaths [1]. Studies 63 
elucidating disease biology are restricted by poor preclinical models and difficulty 64 
acquiring metastatic castration resistant prostate cancer (mCRPC) biopsies [2]. The 65 
genomic landscape of both localized and advanced PC has been recently described 66 
but bulk tumor biopsy genomics only provide a snapshot of the disease landscape [3].. 67 
Moreover, concerns have been raised regarding the ability of bulk biopsy sequencing 68 
to document intra-tumor heterogeneity and clonal evolution. Serial biopsies are 69 
necessary to evaluate changes imposed by therapeutic selective pressures over time, 70 
but their acquisition is challenging, invasive and often not feasible. Less invasive 71 
alternatives (“liquid biopsies”) could be hugely impactful, allowing serial evaluation, and 72 
detecting disease evolution that can influence treatment choices.    73 
 74 
Two main forms of liquid biopsy have emerged: Circulating plasma cell-free DNA 75 
(cfDNA) and circulating tumor cell (CTC) analyses. Whilst measuring cfDNA 76 
concentrations has utility [4], limitations in qualitative analyses deconvoluting intra-77 
patient heterogeneity and accurate calling of copy number aberrations (CNAs), 78 
especially deletions, have been acknowledged [5]. CTCs, shed from solid tumors [6] 79 
and found in the peripheral blood (PB) of patients with both non-metastatic (5-24%) 80 
and metastatic (26-49%) disease [7, 8], can allow the early detection of disease 81 
dissemination, prognostication and benefit from therapy [9, 10]. Indeed, CTC 82 
evaluation may be superior to radiological assessment in determining response to 83 
treatment and outcome. [11-13] 84 
 85 
CTC studies can allow non-invasive, serial, tumor genomic characterization during 86 
treatment, but a major challenge to this has been their detection in significant numbers 87 
to enable genomic, transcriptomic and protein analyses. To overcome these limitations, 88 
apheresis has been suggested to increase CTC yield [14]. Apheresis allows processing 89 
of the whole blood volume by centrifugation, separating blood components (e.g. red 90 
cells, platelets and leukocytes) based on density. Apheresis has a therapeutic role in 91 
the management of hematological disorders and is well tolerated with few safety 92 
concerns [15]. Previous studies have suggested that CTCs can be collected from 93 
apheresis product from patients with and without metastases [14, 16, 17]. CTCs can 94 
have a similar density to mononuclear cells and apheresis can increase CTC 95 
separation from a larger volume of processed blood. We hypothesized that apheresis, 96 
followed by CTC enrichment methods, could allow the safe acquisition of large 97 
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numbers of viable and intact purified CTC populations from patients with advanced PC, 98 
permitting a true liquid biopsy and tumor molecular characterization.  99 
 100 
Materials  and Methods: 101 
Patient selection and clinical assessment 102 
Eligible patients had histologically confirmed mCRPC. Additional eligibility criteria 103 
included: Detectable peripheral blood CTCs (CellSearchTM), good bilateral antecubital 104 
fossa venous access and no coagulopathy. Clinical assessments included medical 105 
history and physical examination, full blood count, biochemical tests and coagulation. 106 
Safety assessments were done during apheresis and after 30-days. All patients 107 
provided written informed consent. The study was conducted in accordance with the 108 
Declaration of Helsinki, with the ethics committee of the Royal Marsden and The 109 
Institute of Cancer Research approving the study. 110 
 111 
Apheresis (method and CTC detection) 112 
Apheresis was performed using a Spectra Optia™ Apheresis System (Terumo, BCT, 113 
Lakewood, CO). Patients were connected to this via two peripheral venous catheters in 114 
each cubital vein. Whole blood was anticoagulated before entering the rotating 115 
centrifuge. Heavier blood elements including erythrocytes migrated to the outside of 116 
the channel, plasma to the centre, and the buffy coat (including mononuclear cells and 117 
CTCs) to the middle. The mononuclear cell layer was removed and the remaining 118 
blood cells and plasma were constantly returned to the patient to the contralateral arm. 119 
Granulocyte-colony stimulating factor was not used. Blood was anticoagulated with 120 
citrate dextrose solution A (2-4 500mL infusion bags were required for each 121 
procedure).  122 
 123 
CTC Enumeration using CellSearch® platform 124 
CTC counts were determined in 7.5mL of PB drawn immediately before, and after, the 125 
apheresis; an aliquot of apheresis product containing 200x106 WBC was transferred to 126 
a CellSave preservative tube (Menarini, Silicon Biosystems) and mixed with 127 
CellSearchTM dilution buffer to a final volume of 8mL. All samples were processed 128 
within 96-hours and CTC counts determined by CellSearch® (Menarini, Silicon 129 
Biosystems). Briefly, cells were subjected to immunomagnetic capture using anti-130 
EpCAM antibodies and stained with antibodies specific for cytokeratin 8, 18 and 19 131 
(CK-PE), CD45 (CD45-APC) and nucleic acid dye (DAPI). Cells were defined as CTCs 132 
when positive for cytokeratin and DAPI and negative for CD45. Images were captured 133 
Research. 
on April 24, 2019. © 2018 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on August 9, 2018; DOI: 10.1158/1078-0432.CCR-18-0862 
6 
using the CellTracks Analyzer II® (Menarini, Silicon Biosystems) and manually 134 
examined to determine the presence of CTC. CellSearch Cartridges were stored in the 135 
dark at 4°C before further analyses. 136 
Single cell isolation and amplification  137 
CellSearch cartridge contents were transferred into fresh Eppendorf tubes, washed 138 
twice with 150μl of phosphate buffered saline, and FACS sorted (FACS Aria III; 139 
Becton, Dickinson and Company) to single CTCs (DAPI+, CK+, CD45-) or WBC 140 
(DAPI+, CD45+, CK-). Sorted single CTC or WBC were whole genome amplified 141 
(WGA) using Ampli1TM (Menarini, Silicon Biosystems) according to the manufacturer 142 
instructions with minor modifications. Cells were lysed, digested for 30-minutes, 143 
adaptor ligated for 3-hours and PCR-amplified. The WGA DNA was purified 144 
(MinEluteTM PCR Purification Kit (Qiagen), quantified using QubitTM (Invitrogen), and 145 
stored at -20 C.  146 
 147 
DNA from biopsies 148 
DNA from formalin fixed paraffin embedded (FFPE) biopsies was extracted using the 149 
QIAampTM DNA FFPE Tissue kit (Qiagen), quantified using QubitTM (Invitrogen), and 150 
evaluated by Illumina FFPE QC kitTM. Whole genome amplification was carried out on 151 
10ng of tumor DNA using WGA2TM (Sigma Aldrich). WGA DNA was purified (MinElute 152 
PCR Purification Kit; Qiagen), quantified (Qubit; Invitrogen), and stored at -20 C. 153 
  154 
Array Comparative Genomic Hybridization (aCGH) 155 
500ng of amplified single CTC DNA was fluorescently labeled with Cy5, and WBC 156 
reference DNA labeled with Cy3 (SureTag Complete DNA Labeling Kit; Agilent 157 
Technologies CA, USA). Labeled DNA was purified and hybridized utilizing the Agilent 158 
SurePrint G3 Human array CGH Microarray Kit, 4x180K. Slides were scanned and 159 
ratios of CTC/WBC determined using CytoGenomics Software v 4.0.3.12 (Agilent 160 
Technologies CA, USA). Log2 ratios of aCGH segments were matched with gene 161 
coordinates to assign per-gene values. Copy states of genes were classified by the 162 
assigned log2 ratio values. Log2 ratio values < −0.25 were categorized as losses; those 163 
> 0.25 as gains; and those in between as unchanged. Amplifications were defined as 164 
smoothed log2 ratio values ≥1.2 and homozygous deletions as the segment log2 ratio 165 
values ≤ -1.2.  166 
 167 
Per-sample CNA burden was calculated as the proportion of the human genome (3000 168 
Mega-base pairs) impacted. Unsupervised hierarchical clustering was performed using 169 
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R (v3.4) with Ward’s method and the Euclidean distances of unique copy number 170 
changes. When clustering samples from multiple tissue types, X chromosome genes 171 
were excluded (aside from the AR gene and ten genes on either side) due to different 172 
reference X-chromosome ploidies (as a female reference was used). Per-patient 173 
functional diversity was derived from cluster dendrograms of CTC samples by 174 
calculating the sum of connecting branches in a dendrogram (from the R package 175 
vegan v2.4.4) and divided by the number of samples.  176 
 177 
FISH analysis  178 
FISH was performed by FFPE hybridization as previously described [22]. Briefly 3-4μM 179 
FFPE sections were deparaffinized, heat pre-treated, pepsin digested and hybridized 180 
with FISH probe hybridization mix overnight at 370C. FISH probes used were: 181 
BRCA2/CEN13q (Abnova); RB1 (Abbott Laboratories); PTEN (10q23)/SE 10; MYC 182 
(8q24)/SE 8 (Leica Microsystems) and a custom-made AR/CEPX probe (Menarini, 183 
Silicon Biosystems). Stringency washes were performed on all slides; for AR, where 184 
the probe was indirectly labelled, a secondary incubation with anti-Digoxigenin-185 
Fluorescein antibody (Roche Diagnostics, USA) was done. Slides were digitally imaged 186 
(Bioview Ltd., Rehovot, Israel) and a pathologist (DNR) evaluated a minimum of 100 187 
tumor cells; the ratios between probes of interest and reference probes were recorded. 188 
Amplification was reported if the ratio was >2; heterozygous loss and homozygous 189 
deletion if at least 1/3 of the cells showed loss of one copy, or loss of all copies, of the 190 
tested probe respectively.  191 
 192 
Organoid culture 193 
For CTC enrichment, 1ml of single cell suspension was immunomagnetically separated 194 
with EasySep™ Epcam positive selection (Stem Cell Technologies) and the selected 195 
fraction used for organoid culture (negative fraction cultured as a control). Isolated cells 196 
were seeded in 3D using growth factor reduced MatrigelTM (Corning) in spheroid-197 
forming suspension in ultra-low attachment surface-coated microplates 198 
(Nunclon Sphera™, ThermoFisher Scientific) utilizing previously described growth 199 
media conditions [23]. Organoids were passaged after 4-6 weeks and cells collected 200 
manually for molecular studies by dissociation with TrypLE (Sigma-Aldrich) for 5 min at 201 
37°C. 202 
 203 
Next generation sequencing   204 
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Whole exome sequencing (WES) was performed using Kapa Hyper Plus library prep 205 
kits and the Agilent SureSelectXT V6 target enrichment system. Paired-end 206 
sequencing was performed using the NextSeqTM 500 (2x150 cycles; Illumina). FASTQ 207 
files were generated from the sequencer’s output using Illumina bcl2fastq2 software 208 
(v.2.17.1.14, Illumina) with the default chastity filter to select sequence reads for 209 
subsequent analysis. All sequencing reads were aligned to the human genome 210 
reference sequence (GRCh37) using the BWA (v. 0.7.12) MEM algorithm, with indels 211 
being realigned using the Stampy (v.1.0.28) package. Picard-tools (v.2.1.0) were used 212 
to remove PCR duplicates and to calculate sequencing metrics for QC check. The 213 
Genome Analysis Toolkit (GATK, v. 3.5-0) was then applied to realign local indels, 214 
recalibrate base scores, and identify point mutations and small insertions and 215 
deletions. Somatic point mutations and indels were called using MuTect2 by comparing 216 
tumor DNA to germline control and copy number estimation was obtained through 217 
modified ASCAT2 package.  218 
 219 
 220 
Results 221 
Patient Characteristics 222 
From November 2015 to July 2017, 14 eligible mCRPC patients with detectable CTCs 223 
by CellSearchTM were enrolled (median age 70.4 years; range 60-77); time from PC 224 
diagnosis to procedure ranged from 2-11.6 years (mean: 6.2 years; median: 3.9 years). 225 
Median PSA level at apheresis was 506ng/mL (range: 41-6089 ng/mL); all 14 (100%) 226 
had metastatic bone disease. Prior to apheresis, patients had received 1-5 lines of 227 
systemic therapy for CRPC (Supplementary Table 1, Supplementary Figure 1a). At 228 
apheresis, none of the subjects were receiving active treatment other than androgen 229 
deprivation.  230 
 231 
The apheresis workflow is depicted in Figure 1a.  Each apheresis procedure lasted 232 
between 90-160 minutes; apheresis product volume ranged from 40-100 mL 233 
(Supplementary Table 2). Apheresis was well tolerated with no related adverse 234 
events recorded during the procedure or in the 30-day follow-up. Neutrophil and 235 
lymphocyte counts did not change significantly following apheresis (Supplementary 236 
Figure 1b). 237 
 238 
CTC counts 239 
The mean CTC count taken before and after apheresis was 167 and 193, per 7.5mLs 240 
of peripheral blood (PB), respectively. Surprisingly, the CTC count did not decrease 241 
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significantly following apheresis (p=0.48). The average inferred CTC harvest from an 242 
apheresis (mean volume = 59.5mL) was 12546, with apheresis yielding a 90-fold 243 
average increased yield. (p<0.001) (Figure 1b and Supplementary Table 2).  244 
 245 
 246 
Single CTC genomic profiling 247 
To validate the serial WGA and array CGH that we performed on single CTCs, we first 248 
used normal male and female DNA (aCGH verified by Agilent), as well as single white 249 
blood cell (WBC) amplified DNA, and showed that there was no bias amplifications or 250 
deletions. (Supplementary Figure 2a and 2b). Extracted single CTC DNA from a 251 
patient with known tumor biopsy CNAs was then evaluated, confirming robust CNA 252 
calling. WGA of 1µL of serially diluted samples (starting DNA templates: 10ng/µL, 253 
1ng/µL, 0.1ng/µL and 0.03ng/µL) showed no amplification bias with consistent calling 254 
of gains and losses at all dilutions (Supplementary Figure 2c).  255 
 256 
We then analyzed 205 single CTC aCGH genomic profiles for CNAs from the 257 
apheresis products of 14 patients with 185 CTC (90%) showing complex genomic copy 258 
change profiles and 20 (10%) cells having relatively flat genomic copy number profiles. 259 
Surprisingly, only 2 of the evaluated 14 patients had cell populations with both flat and 260 
cancer-like aCGH profiles suggesting that these sorted cells could be associated with 261 
specific tumor sub-types or induced by some treatments. We then aggregated the 262 
aCGH copy number profiles of all the individual CTCs and showed that the overall 263 
profile matched that previously reported for advanced PC whole biopsy exomes [18] 264 
(Figure 1c). Details for individual CTCs per patient are shown in Supplementary Table 265 
3.   266 
 267 
Tumor biopsies (treatment-naïve diagnostic biopsies and/or metastatic biopsies) were 268 
available for 12 of these 14 patients; these samples were also evaluated. Copy number 269 
traces of single CTCs and matching, same patient, biopsies showed broadly similar 270 
genomic profiles (Figure 1c, Supplementary Figure 3), and again matched that of 271 
publically available data [18]. Differences were frequently observed between treatment-272 
naïve biopsies and castration resistant CTCs including AR gain (X chromosome), MYC 273 
gain (8q) and RB1 loss (chromosome 13) likely reflecting tumor evolution under 274 
treatment selective pressures (Supplementary Figure 4). High concordance between 275 
single CTC genomic profiles and contemporaneous, same patient, metastatic biopsies 276 
was seen, although intra-patient genomic heterogeneity was discernable from the 277 
single CTC analyses but not the bulk biopsy analyses.  278 
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 279 
 280 
CTC diversity 281 
Overall, the genomic analyses of 185 single CTCs from 14 patients (Figure 2a) 282 
revealed that some patients had highly homogenous CTC CNA traces (Figure 2a, left) 283 
while others had highly diverse single CTC CNA traces (Figure 2a, right) with many 284 
lethal PCs displaying inter-cell heterogeneity. This may be related to disease 285 
phenotypes or acquired treatment resistance mechanisms (AR and MYC gain at 286 
chromosomes X and 8q respectively; BRCA2/RB1 locus loss at chromosome 13).  287 
There was no significant correlation between median percentage genome alteration 288 
and intra-patient, inter-cell, diversity (Figure 2b) suggesting that this was due to true 289 
clonal diversity rather than aberration accumulation. Despite this, the unsupervised 290 
hierarchical clustering of all the CNA data from individual CTCs and same patient 291 
biopsies indicated that most samples from one patient clustered together 292 
(Supplementary Figure 3).  293 
 294 
Intra-patient heterogeneity and tumor evolution 295 
As depicted in Figure 2a (far left patients), the minority of patients had highly 296 
homogeneous CTC, including P09 (Figure 3a); his contemporaneous mCRPC biopsy 297 
had a virtually identical CNA profile to these CTCs. Most evaluated patients had 298 
heterogeneous CTC CNA profiles that gross biopsy genomic analyses could fail to 299 
identify. To further interrogate this intra-patient heterogeneity, we studied additional 300 
cells in patient P13 who had heterogeneous CTCs, with CNA data suggesting distinct 301 
groups of cells (Figure 3b). Some CTCs clustered with his diagnostic prostatectomy 302 
sample, while others clustered with the mCRPC bone biopsy, with a breakpoint in the 303 
PIK3R1 locus including most of chromosome 5q (Figure 3c). A third group of cells was 304 
also apparent, displaying more complex genomic aberrations.  305 
 306 
FISH (fluorescence in-situ hybridization) analyses of the 5q21.1 locus was then 307 
performed on both the HSPC sample and the metastasis and revealed the presence of 308 
distinct copy number aberrant cells, with 5q21.1 being either gained, normal or lost in a 309 
mixed cell population. Overall, these analyses indicated that these three copy-states 310 
were equally common in the prostatectomy. Over time and following treatment, the 311 
proportion of tumor cells with 5q copy gain increased as shown in the mCRPC biopsy 312 
and apheresis CTCs and as confirmed by tissue FISH analyses (Figures 3c and 3d). 313 
 314 
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We then studied patient P03 since his CTC CNA profiles were also highly 315 
heterogeneous and multiple tumor samples taken at different time points were 316 
available, including a transurethral resection of the prostate (TURP) with four 317 
geographically and morphologically distinct regions (A, B, C, D) which were micro-318 
dissected (Figure 4a). aCGH genomic profiles of these regions identified intra-patient 319 
heterogeneity (Figure 4b). Homozygous deletion of BRCA2 and 8q gain was present 320 
in all four regions; however, loss of chromosome 18 was only present in Areas C and D 321 
while gain of 7q was only present in Areas A and C. The CNA profile of a lymph node 322 
(LN) biopsy acquired from this patient 6 years later, following treatment with docetaxel, 323 
enzalutamide and cabazitaxel, identified the BRCA2 homozygous deletion and 8q gain, 324 
as well as previously undetected AR amplification and 17q gain (Figure 4b).  325 
 326 
In patient P03, we performed whole exome sequencing (WES) of the microdissected 327 
TURP regions. This identified truncal pathogenic mutations of SPOP (p.Trp131Cys) 328 
and FOXA1 (p.His168del), with intra-patient heterogeneity of other mutations indicating 329 
that regions A and C had similar mutation profiles when compared to regions B and D 330 
of the TURP, with the later LN biopsy WES identifying a mixture of these cell 331 
populations (Figure 4c). Single CTC analyses acquired at a later time point by 332 
apheresis also detected this heterogeneity, delineating this cancer’s evolution as 333 
depicted by unsupervised hierarchal clustering of 13 CTCs, 4 micro-dissected TURP 334 
areas, the gross biopsy, and the LN biopsy (Figure 4d and 4e). Figure 4d highlights 335 
key genomic differences in commonly altered pathways in these samples, with 336 
heterogeneous PTEN and BRCA2 loss in different sub-clones. FISH analysis of TURP 337 
tissue using MYC and BRCA2 probes revealed that some TURP tumor cells had 338 
concurrent MYC amplification and BRCA2 homozygous deletion (Figure 4f), while 339 
others had MYC amplification but no BRCA2 loss indicating that the latter was probably 340 
sub-clonal and occurred later, as indicated by the single CTC analyses (Figure 4e). 341 
 342 
The apheresis from patient P05 also revealed heterogeneous CTCs; we successfully 343 
generated organoid cultures from these (Supplementary Figure 5a and 5b) utilizing 344 
previously described methods [19]. The CNA profile of these organoids clustered with 345 
this patient’s CTCs with two genomically divergent sub-clones in culture 346 
(Supplementary Figure 5c) with both sub-clones detectable in the CTC analyses 347 
(Supplementary Figure 5c, 5d) indicating that CTC-derived organoid culture can 348 
recapitulate this diversity. 349 
   350 
Conclusions/Discussion  351 
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Liquid biopsy by apheresis is non-invasive and well-tolerated, increasing CTC yield a 352 
hundred-fold from mCRPC patients. Apheresis did not significantly impact blood CTC 353 
counts suggesting constant replenishment or inefficient capture. Apheresis facilitated 354 
the interrogation of tumor genomics, inter-patient genomic heterogeneity, and the 355 
dissection of PC evolution. We show for the first time that the genomic landscape of 356 
PC CTCs captured by apheresis mirrors that of mCRPC biopsy exomes validating 357 
these CTC capture methods [18]. Copy number traces of individual CTCs frequently 358 
closely resembled same patient biopsies, with evidence for CTC CNAs evolving over 359 
time due to therapeutic pressures (including gains in MYC and AR). Critically, sub-360 
clonal CNAs not easily discernable from bulk biopsy analyses were easily detected by 361 
single CTC analyses dissecting disease clonal evolution.  362 
 363 
Yields of evaluable single cells decrease significantly through our experimental 364 
procedures; stringent settings in FACS sorting to allow isolation of only pure single 365 
cells results in a 60-80% retention rate of CTCs from CellSearchTM cartridges. DNA 366 
from approximately another 20% of these cells fail quality control after whole genome 367 
amplification. Therefore, in order to end up with sufficient CTCs for genomic analyses, 368 
a high number of cells are required, making the concentrated apheresis product a 369 
much more efficient source than peripheral blood. 370 
 371 
Surprisingly, we identified by unsupervised clustering varying degrees of intra-patient 372 
heterogeneity with some patients having highly homogeneous single CTCs but most 373 
having intra-patient CTC genomic diversity. Some CTCs resembled diagnostic biopsies 374 
with others genomically mirroring metastases. We envision that the dynamic analyses 375 
of these clones by serial, repeated, apheresis before, during, and after treatment will 376 
not only dissect disease evolution but also help guide therapeutic switch decisions. 377 
Such heterogeneity remains difficult to identify from circulating free DNA, with the 378 
analyses of CTCs captured by apheresis allowing a more precise evaluation of 379 
emerging clones/sub-clones. Early identification of resistant clones can be utilized to 380 
reverse treatment failure, guiding drug combination administration or the serial 381 
utilization of drugs not tolerated when administered together. We propose that serial, 382 
multiple, apheresis procedures should now be embedded in drug trials to analyze 383 
tumor clones/sub-clone eradication/evolution during therapy to further evaluate this 384 
strategy while also generating estimates of CTC counts for monitoring response to 385 
therapy [20].  386 
 387 
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Further work is also now needed to explore the clinical implications of this diversity in 388 
intra-patient heterogeneity, evaluating whether distinct genomic subtypes of advanced 389 
PC display different levels of single CTC diversity.  Moreover, further optimization of 390 
methodology generating successful organoid growth from apheresis products, along 391 
with subsequent molecular and functional analyses to confirm that these CTC-derived 392 
organoids can model mCRPC ex vivo, may also support the future study of drug testing 393 
in CTC organoid cultures.  394 
 395 
We acknowledge the limitations of the data presented, particularly with regards to the 396 
limited cohort size and the fact that all the patients were treated at one tertiary cancer 397 
center making it difficult to draw broader clinical conclusions.  In order for apheresis to 398 
have widespread utility it needs to be easily accessible, with high throughput CTC 399 
isolation from patients with other cancer types and with lower burden disease [21]. 400 
Moreover, improved methods to enhance CTC mobilization and yield through 401 
chemokine axis manipulation are warranted with such procedures potentially having 402 
therapeutic utility in patients with lower burden disease.  403 
 404 
Moving forward, studies are needed to identify the optimal number of individual CTCs 405 
from one patient to sufficiently interrogate heterogeneity yet minimize cost. Low 406 
coverage whole genome next generation sequencing with barcoding of DNA from each 407 
CTC may allow this, as well as exploration of single cell RNA sequencing to better 408 
understand resistance mechanisms.  Direct comparison of CTCs acquired by 409 
apheresis with both CTCs and cfDNA from peripheral blood, as well as with single cells 410 
dissociated from tissue should be pursued. Finally, studies to evaluate the large 411 
numbers of immune cells in the apheresis product from these patients are also merited. 412 
 413 
In conclusion, we have demonstrated that the analyses of single CTCs captured by 414 
apheresis permits the identification of intra-patient tumor genomic heterogeneity 415 
previously missed by bulk biopsy analyses, providing previously undescribed detail on 416 
different mCRPC sub-clones. Although the study of biopsies remains a gold standard, 417 
the challenges of acquiring serial biopsies and disaggregating these to single cell 418 
suspensions to study disease evolution remain. We now posit that successfully and 419 
safely improving CTC yield for genomic analyses by apheresis is highly advantageous 420 
and has major potential implications for more precise cancer care.  421 
 422 
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Figure legends:  424 
Figure 1. Overview of methodology, CTC counts and the overall genomic 425 
analyses: a) Methodology workflow of the study; b) CTC counts from 7.5mL of 426 
peripheral blood taken pre-apheresis, post-apheresis and compared to inferred 427 
harvested CTC counts in the total volume of apheresis product. c) The top plot 428 
represents the frequency of the genomic aberrations found in 185 single CTCs 429 
harvested by apheresis from 14 mCRPC patients; the middle plot represents the 430 
frequency of genomic aberrations from 150 mCRPC exomes (SU2C/PCF cohort), and 431 
the lower plot represents the frequency of genomic aberrations from available tissue 432 
biopsies from 12/14 patients. Chromosomes are shown across the x-axis whereas the 433 
y-axis represent the frequency of gains, losses, amplification and homozygous 434 
deletions. Gains are depicted in light pink, losses are depicted in light blue, 435 
amplification in dark red and homozygous/deep deletions are in dark blue. *aCGH of 436 
tissue biopsies were performed using female reference DNA (Agilent).  437 
 438 
Figure 2. Individual CTC CNA data depicting complex intra-patient and inter-439 
patient genomic diversity: a) Unsupervised hierarchical clustering heatmap, based 440 
on Euclidean distance, of each analyzed individual CTC from each apheresis patient 441 
based on CTC CNA. Each patient is depicted with one color as shown on the phenobar 442 
at the top of the heatmap. The heatmaps of each individual patient are organized by 443 
their intra-patient diversity score from left to right. Chromosomal CNA are shown from 444 
top to bottom for each individual CTC; copy number gains are depicted in light blue, 445 
losses in pink, with amplifications and homozygous deletions in dark blue and dark red 446 
respectively. b) Box plot showing the percentage genome altered (%GA) for each of 447 
the patients. Each filled circle in the box plot represents the percentage genome 448 
altered of a single CTC.   449 
 450 
Figure 3. Intra-patient CTC genomic heterogeneity. a) Individual CTC genome plots 451 
of patient P09 show very homogenous CTCs similar to a metastatic bone biopsy. b) 452 
Heat map depicting CNA of 23 CTCs (grey bars) and 2 tumor biopsies (black bars) 453 
from patient P13 showing two different sub-clones, readily visualized by focusing on 454 
chromosome 5q, and an additional group of highly heterogeneous CTCs (far left). c) 455 
FISH analysis of treatment naïve prostatectomy tissue and a bone mCRPC biopsy 456 
from patient P13 using probes for 5p11(red) and 5q21.1 (green). d) A schematic 457 
diagram showing the percentage of cells with copy number alterations on 5q21.1 with 458 
disease progression from the time of the prostatectomy until apheresis in patient P13.  459 
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Figure 4. Intra-patient genomic heterogeneity in patient P03: a) 461 
Tissue micrographs from four distinct TURP regions shown, depicting intra-patient 462 
heterogeneity of tumor morphology with A and C, as well as B and D, similar to one 463 
another. In regions A and C glandular differentiation is noticeable with small, 464 
monomorphic, hyperchromatic nuclei and inconspicuous nucleoli, whereas in regions B 465 
and D a more solid arrangement with pleomorphic nuclei and an open chromatin 466 
pattern with large, discernible nucleoli is seen. b) Genome profiles of these TURP 467 
regions presented by aCGH. Intra-patient heterogeneity between the 4 areas is 468 
highlighted by dashed red lines; regions A and C had gains of 17q and 12q and losses 469 
of 3p whereas regions B and D had loss of chromosome 18 and 2p. All areas had 470 
homozygous deletion of the BRCA2 genomic locus. A metastatic lymph node biopsy 471 
taken at a later date had multiple new aberrations including new AR amplification. c) 472 
Exome sequencing revealed that while all samples had an SPOP mutation there was 473 
intra-patient heterogeneity as identified by morphology and copy number analysis. d) 474 
Heatmap depicting CNA heterogeneity for 12 selected prostate cancer genes with 475 
dendrogram utilizing hierarchical clustering of CNA data, based on Euclidean distance, 476 
for these tumor tissues and CTCs. Individual CTC are depicted as C#, with # depicting 477 
CTC number; “A” represents archival TURP material, “M” the metastatic lymph node 478 
biopsy, with A-A, A-B, A-C and A-D respectively representing TURP tissue from 479 
regions A, B, C and D respectively. e) Chromosome 13 plot showing heterogeneous 480 
BRCA2 loss in different CTCs and biopsies. f)  FISH analysis of TURP tumor tissue 481 
with BRCA2 probe in green and MYC probe in red; BRCA2 was homozygously deleted 482 
in most but not all cells (green arrows depict tumor cells with BRCA2 heterozygous 483 
loss or no copy loss).  484 
 485 
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Supplementary Figure legends:  488 
Supplementary Figure 1. Clinical data: a) Summary of prior treatments of all 14 489 
patients prior to apheresis. b) A histogram presenting the lymphocyte and neutrophil 490 
counts (x109/L) in peripheral blood pre- and post-apheresis procedures. 491 
 492 
Supplementary Figure 2. Summary of the validation steps. a) Male vs female: 493 
Genome plot of amplified male DNA vs amplified female DNA using the Ampli 1 kit. b) 494 
WBC vs WBC: Genomic profile of Ampli1 amplified WBCs against another WBC. c) 495 
Dilution evaluation: Genomic aberrations of an mCRPC sample with known CNA 496 
diluted serially to 10ng/µL, 1ng/µL, 0.1ng/µL, and 0.03ng/µL with all dilutions 497 
generating similar profiles after Ampli1TM WGA and aCGH. Gains and amplification 498 
depicted in blue, and losses and homozygous/deep deletion in red.  499 
 500 
Supplementary Figure 3. Unsupervised clustering analyses of all samples: Fan 501 
presentation of unsupervised clustering of all CTCs, tissue biopsies and organoids 502 
evaluated in this study. Each CTC is annotated as a circle, each tissue sample as a 503 
square, and an organoid as a triangle. Each apheresis patient is depicted by a color. 504 
CTCs largely cluster with tumor biopsies from the same patient although as a result of 505 
intrapatient heterogeneity some clustered away. 506 
 507 
Supplementary Figure 4: Heatmaps presenting unsupervised hierarchical 508 
clustering based on CNA and Euclidean distance, of all the samples for each 509 
patient. Each individual patient is depicted by number from left to right, with 510 
chromosomal aberrations from top to bottom. Tumor biopsies are identified by black 511 
bars, and CTCs by green bars, at the bottom of the heatmap. 512 
 513 
Supplementary Figure 5: Organoid cultures of CTCs acquired by apheresis from 514 
patient P05: a) Dendrogram and heat map of hierarchical clustering, based on 515 
Euclidean distance, for patient P05 evaluating CTC (green bars) and organoid CNAs 516 
(red). b) Micrographs of two organoids from P05 with scale bar in bottom left (100µm). 517 
c) Phylogenetic tree showing the cultured organoids have CNA that cluster with CTCs. 518 
d) Two organoids and 3 CTCs with truncal CNA including shared BRCA2 loss and AR 519 
amplification but sub-clonal chromosome 1 aberrations.  520 
Supplementary Table legends  521 
Supplementary Table 1: Baseline characteristics of study patients (n=14). 522 
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*All values given are at time of apheresis unless otherwise specified. 523 
∧The Eastern Cooperative Oncology Group (ECOG) performance status score ranges 524 
from 0 to 5, with 0 indicating no symptoms and higher scores indicating increasing 525 
disability. 526 
 527 
Supplementary Table 2: Summary of the CTC and WBC counts from both peripheral 528 
blood and apheresis product for all 14 patients, with additional clinical characteristics 529 
including sites of disease at apheresis and time to disease progression following 530 
apheresis procedure (when available). [ND = Not determined; WBC = White Blood 531 
Cells; CTC = Circulating Tumor Cells; PB = Peripheral Blood; Tot.Vol = Total Volume; 532 
Inc. = Increase] 533 
 534 
Supplementary Table 3: Summary of individual CTCs per patient with percentage of 535 
the genome covered by a copy number segment and percentage of genes that are 536 
altered.  537 
 538 
 539 
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